Payment overview · 2025
General Payments
$1,621.20
67 reported records · 15 companies
Healthcare provider profile · identity verified
Arkady Pinkhas
Allopathic & Osteopathic Physicians|Internal Medicine · FORSET HILLS, NY · NPI 1861587438
Verified facts
What the public records show
CMS Open Payments records show Arkady Pinkhas received $1,621.20 in general payments during 2025 across 67 reported records.
ABBVIE INC. accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Nurtec Odt, Trelegy Ellipta, Ubrelvy, Xifaxan, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 742 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viibryd by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 455 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 345 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vesicare as an associated drug or biological on 41 records involving 41 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vesicare by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 742 claims for Linzess by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Nurtec Odt by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $401.71 | 24.8% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $241.48 | 14.9% | 10 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $215.15 | 13.3% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $192.88 | 11.9% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.22 | 6.9% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $87.43 | 5.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $69.94 | 4.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.29 | 3.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.03 | 3.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.31 | 2.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.56 | 2.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.14 | 2.0% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $27.20 | 1.7% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $25.00 | 1.5% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $22.86 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,621.20 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $286.76 | 16 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $261.76 | 15 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $215.15 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $192.88 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $152.61 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $114.95 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $111.22 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $93.77 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $87.43 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $87.43 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $69.94 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $69.89 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $61.29 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.03 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.31 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.31 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.14 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 324 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 183 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 211 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 742 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 76 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 109 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 455 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
324 | 46 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
742 | 91 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
228 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
455 | 50 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
345 | 42 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Vesicare open payments reported associated product |
CMS Open Payments — General Payments 41 supporting records · 41 recipient NPIs · example record 1238616716 |
Vesicare · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
211 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
108 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
132 | 31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
109 | 17 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
742 | 91 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
183 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diclofenac Sodium | Diclofenac Sodium | 839 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 747 | 104 |
| Linzess | Linaclotide | 742 | 91 |
| Gabapentin | Gabapentin | 518 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 510 | 67 |
| Losartan Potassium | Losartan Potassium | 499 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 486 | 67 |
| Vascepa | Icosapent Ethyl | 479 | 57 |
| Zenpep | Lipase/Protease/Amylase | 455 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 454 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 400 | 55 |
| Metformin Hcl | Metformin Hcl | 396 | 49 |
| Sertraline Hcl | Sertraline Hcl | 375 | 59 |
| Myrbetriq | Mirabegron | 345 | 42 |
| Creon | Lipase/Protease/Amylase | 324 | 46 |
| Dexilant | Dexlansoprazole | 317 | 36 |
| Dexlansoprazole Dr | Dexlansoprazole | 293 | 40 |
| Simvastatin | Simvastatin | 276 | 38 |
| Ventolin Hfa | Albuterol Sulfate | 275 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 274 | 57 |
| Omeprazole | Omeprazole | 264 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 261 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 252 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 239 | 55 |
| Montelukast Sodium | Montelukast Sodium | 234 | 29 |
| Synthroid | Levothyroxine Sodium | 228 | 30 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 225 | 24 |
| Farxiga | Dapagliflozin Propanediol | 211 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 32 |
| Memantine Hcl Er | Memantine Hcl | 207 | 35 |
| Allopurinol | Allopurinol | 187 | 24 |
| Ibuprofen | Ibuprofen | 187 | 56 |
| Furosemide | Furosemide | 184 | 29 |
| Eliquis | Apixaban | 183 | 25 |
| Carvedilol | Carvedilol | 181 | 28 |
| Azithromycin | Azithromycin | 178 | 115 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 168 | 19 |
| Restasis | Cyclosporine | 165 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 165 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 159 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 158 | 26 |
| Clonidine Hcl | Clonidine Hcl | 156 | 24 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 145 | 15 |
| Lisinopril | Lisinopril | 144 | 21 |
| Enalapril Maleate | Enalapril Maleate | 140 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 132 | 31 |
| Naproxen | Naproxen | 131 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 128 | 18 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 125 | 14 |
| Famotidine | Famotidine | 124 | 25 |
| Potassium Chloride | Potassium Chloride | 122 | 17 |
| Trazodone Hcl | Trazodone Hcl | 122 | 12 |
| Buspirone Hcl | Buspirone Hcl | 121 | 23 |
| Januvia | Sitagliptin Phosphate | 121 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 116 | 21 |
| Donepezil Hcl | Donepezil Hcl | 114 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 113 | 14 |
| Nitroglycerin | Nitroglycerin | 113 | 14 |
| Procto-Med Hc | Hydrocortisone | 113 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 113 | 19 |
| Alendronate Sodium | Alendronate Sodium | 112 | 13 |
| Silver Sulfadiazine | Silver Sulfadiazine | 111 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 111 | 21 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 109 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 109 | 17 |
| Nexium | Esomeprazole Magnesium | 108 | 14 |
| Ezetimibe | Ezetimibe | 105 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 37 |
| Lidocaine | Lidocaine | 103 | 21 |
| Glipizide | Glipizide | 102 | 15 |
| Meclizine Hcl | Meclizine Hcl | 102 | 22 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 101 | 27 |
| Glimepiride | Glimepiride | 95 | 12 |
| Jardiance | Empagliflozin | 95 | 13 |
| Finasteride | Finasteride | 88 | 12 |
| Atenolol | Atenolol | 87 | suppressed |
| Repatha Sureclick | Evolocumab | 86 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 15 |
| Nitroglycerin Patch | Nitroglycerin | 84 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 12 |
| Jublia | Efinaconazole | 83 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 82 | 17 |
| Meloxicam | Meloxicam | 81 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 79 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 77 | 21 |
| Levofloxacin | Levofloxacin | 77 | 51 |
| Mupirocin | Mupirocin | 77 | 24 |
| Nurtec Odt | Rimegepant Sulfate | 76 | suppressed |
| Proctozone-Hc | Hydrocortisone | 74 | 12 |
| Lorazepam | Lorazepam | 73 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 15 |
| Crestor | Rosuvastatin Calcium | 70 | suppressed |
| Hydrocortisone | Hydrocortisone | 70 | 13 |
| Ammonium Lactate | Ammonium Lactate | 69 | 14 |
| Celecoxib | Celecoxib | 68 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 68 | 11 |
| Livalo | Pitavastatin Calcium | 65 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 63 | 11 |
| Ramipril | Ramipril | 61 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | suppressed |
| Trulicity | Dulaglutide | 58 | suppressed |
| Ketoconazole | Ketoconazole | 57 | suppressed |
| Invokana | Canagliflozin | 56 | suppressed |
| Memantine Hcl | Memantine Hcl | 56 | suppressed |
| Dutasteride | Dutasteride | 53 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 52 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 49 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 48 | suppressed |
| Nifedipine Er | Nifedipine | 48 | suppressed |
| Clotrimazole | Clotrimazole | 47 | 13 |
| Mupirocin | Mupirocin Calcium | 47 | suppressed |
| Valsartan | Valsartan | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 31 |
| Flector | Diclofenac Epolamine | 43 | suppressed |
| Loperamide | Loperamide Hcl | 43 | 15 |
| Gemtesa | Vibegron | 42 | suppressed |
| Lubiprostone | Lubiprostone | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Canasa | Mesalamine | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Cilostazol | Cilostazol | 37 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 37 | suppressed |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 35 | suppressed |
| Fluocinonide | Fluocinonide | 35 | 11 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Trulance | Plecanatide | 34 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Xifaxan | Rifaximin | 30 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Cyclosporine | Cyclosporine | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 28 | suppressed |
| Mesalamine | Mesalamine | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 26 | suppressed |
| Toviaz | Fesoterodine Fumarate | 26 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Bystolic | Nebivolol Hcl | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Qbrexza | Glycopyrronium Tosylate | 24 | suppressed |
| Tavaborole | Tavaborole | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Benicar | Olmesartan Medoxomil | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Opzelura | Ruxolitinib Phosphate | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Xiidra | Lifitegrast | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Norvasc | Amlodipine Besylate | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Prevacid | Lansoprazole | 19 | suppressed |
| Rapaflo | Silodosin | 19 | suppressed |
| Toprol Xl | Metoprolol Succinate | 19 | suppressed |
| Ztlido | Lidocaine | 19 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Epinephrine | Epinephrine | 18 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 18 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 18 | suppressed |
| Tacrolimus | Tacrolimus | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 11 |
| Ciclopirox | Ciclopirox Olamine | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 16 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Plavix | Clopidogrel Bisulfate | 14 | suppressed |
| Rozerem | Ramelteon | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Mitigare | Colchicine | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Zetia | Ezetimibe | 13 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Baraclude | Entecavir | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Horizant | Gabapentin Enacarbil | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lopressor | Metoprolol Tartrate | 12 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Uloric | Febuxostat | 12 | suppressed |
| Celebrex | Celecoxib | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clindamycin Phos-Benzoyl Perox | Clindamycin Phos/Benzoyl Perox | 11 | suppressed |
| Cymbalta | Duloxetine Hcl | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Flomax | Tamsulosin Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Licart | Diclofenac Epolamine | 11 | suppressed |
| Pimecrolimus | Pimecrolimus | 11 | suppressed |
| Prozac | Fluoxetine Hcl | 11 | suppressed |
| Vesicare | Solifenacin Succinate | 11 | suppressed |
| Viibryd | Vilazodone Hcl | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,621.20 · 67 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, CREON, ELIQUIS, FARXIGA, GLYCATE, IBSRELA, JARDIANCE, LINZESS, NURTEC ODT, OTEZLA, PANCREAZE, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Symbravo, TRELEGY ELLIPTA, UBRELVY, Veozah, XIFAXAN, ZENPEP | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error